...
首页> 外文期刊>Angewandte Chemie >Crosslinking Allosteric Sites on the Nucleosome
【24h】

Crosslinking Allosteric Sites on the Nucleosome

机译:核小体上的交联变构位点

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Targeting defined histone protein sites in chromatin is an emerging therapeutic approach that can potentially be enhanced by allosteric effects within the nucleosome. Here we characterized a novel hetero-bimetallic compound with a design based on a nucleosomal allostery effect observed earlier for two unrelated drugs-the Ru-II antimetastasis/antitumor RAPTA-T and the Au-I anti-arthritic auranofin. The Ru-II moiety binds specifically to two H2A glutamate residues on the nucleosome acidic patch, allosterically triggering a cascade of structural changes that promote binding of the Au-I moiety to selective histidine residues on H3, resulting in cross-linking sites that are over 35 angstrom distant. By tethering the H2A-H2B dimers to the H3-H4 tetramer, the hetero-bimetallic compound significantly increases stability of the nucleosome, illustrating its utility as a site-selective cross-linking agent.
机译:染色体中定义的组蛋白蛋白位点是一种新出现的治疗方法,其可以通过核小体内的变构效应来增强。 在这里,我们的特征在于一种新的异质 - 双金属化合物,其具有基于前面观察到的两个无关药物 - Ru-II antimetastasis / Antritumor Rapta-T和Au-I抗关节炎奥拉诺素的核体仿生效应的设计。 Ru-II部分特异性结合核小体酸性贴剂上的两个H 2 A谷氨酸残基,构成促进Au-1部分与选择性组氨酸残基的结构变化的级联突出的结构变化,导致交联位点 35埃遥远。 通过将H 2-H 2B的二聚体束缚至H3-H4四聚体,杂双金属化合物显着提高了核小体的稳定性,示出其作为位点选择性交联剂的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号